Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostatic Neoplasms: full-pipeline trial registry
19 of 66 indexed Prostatic Neoplasms trials are currently recruiting.
Corpus placement: #211 of 28,707 conditions by registered trial count.
66 US clinical trials · 19 currently recruiting · #211 of 28,707 conditions by registered trial count
Prostatic Neoplasms: 66 US clinical trials tracked, 19 recruiting.
Prostatic Neoplasms is the subject of 66 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 22 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 8 of these trials.
Enrollment posture brief
Registry condition prostatic-neoplasms
OPEN 19 | RECR 29% | LATE 22 | EARLY 32 | RANK #211 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Cystic Fibrosis (29% recruiting · 170 trials)
Prostatic Neoplasms lists 19 open slots (29% of 66 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostatic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostatic Neoplasms is recruiting below its size-band peers.
19 of 66 indexed trials (28.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostatic Neoplasms trials is spread across many organizations.
Janssen Research & Development accounts for 8 of 66 trials (12.1%). 39 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostatic Neoplasms enrolment sits around 144 participants.
Median target enrolment is 144 among the 66 trials that report a genuine target (sentinel values excluded). 25 of those (37.9%) plan for fewer than 100 participants.
-
Prostatic Neoplasms research is mostly interventional.
57 interventional and 9 observational studies make up this index (86.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
66 total, page 1 of 2
Prostate Active Surveillance Study
University of Washington
NCT00756665
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme
NCT06925737
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Bayer
NCT07406282
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme
NCT06136650
Collection of Blood From Patients With Prostate Cancer
National Cancer Institute (NCI)
NCT00923221
Men at High Genetic Risk for Prostate Cancer
National Cancer Institute (NCI)
NCT03805919
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Clarity Pharmaceuticals
NCT06056830
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
National Cancer Institute (NCI)
NCT01834001
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06751329
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development
NCT07082920
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Icahn School of Medicine at Mount Sinai
NCT07285057
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
NCT05765500
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics
NCT05413850
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Cancer Institute (NCI)
NCT05616650
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development
NCT07319871
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
The Methodist Hospital Research Institute
NCT01913106
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
Inova Health Care Services
NCT07335224
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Janssen Research & Development
NCT03767244
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals
NCT02531516
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Merck Sharp & Dohme
NCT03834493
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals
NCT01946204
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
NCT04720157
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
University of Sydney
NCT02446405
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
NCT00579163
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals
NCT02257736
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company
NCT05288166
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
University of Sydney
NCT02446444
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Janssen Pharmaceutica N.V., Belgium
NCT04557059
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals
NCT04689828
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Janssen Research & Development
NCT04898634
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development
NCT04644770
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development
NCT04577833
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Columbia University
NCT03824275
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
National Institutes of Health Clinical Center (CC)
NCT04652973
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics
NCT02266745
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT03173924
Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
Dana-Farber Cancer Institute
NCT05918263
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals
NCT02123758
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development
NCT05022849
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Sanofi
NCT00519285
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Cougar Biotechnology
NCT00638690
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Merck Sharp & Dohme
NCT03834506
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Exelixis
NCT01605227
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Bayer
NCT02043678
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Merck Sharp & Dohme
NCT03834519
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
Sanofi
NCT00417079
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
Blue Earth Diagnostics
NCT02443571
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
NCT00643617
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 14 |
| Phase 3 | 21 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostatic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostatic Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostatic Neoplasms page
66 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Prostatic Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Prostatic Neoplasms trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Neoplasms condition card totals 66 registered trials; most-linked intervention Prednisone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.